Traditional medicines in the spotlight at US/China meeting
This article was originally published in Scrip
The regulation of traditional Chinese medicines (TCMs) was the central topic of discussion at the latest annual meeting between the US Pharmacopeial Convention and the Chinese Pharmacopoeia Commission.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.